Literature DB >> 122409

Inhibition of gonadotropin and prolactin release by dopamine: effect of endogenous estradiol levels.

S J Judd, J S Rakoff, S S Yen.   

Abstract

The influence of endogenous estradiol (E2) levels on gonadotropin and PRL sensitivity to dopamine (DA) infusion (4 micrograms/kg/min) was assessed at different stages of the follicular phase of the menstrual cycle. Basal LH and FSH levels were comparable in day 2 and day 12 subjects, and despite a 4-fold increase in E2 concentration, the inhibition of LH by DA was small and quantitatively similar and there was no discernible effect on FSH in either group. In marked contrast, day 14 subjects with an elevated basal LH level exhibited a dramatic increase in the sensitivity of LH and FSH to DA inhibition. Further, a remarkable rebound release for LH but not FSH occurred on the termination of DA infusion. There was a significant correlation between basal LH and response to DA (r = 0.979). This unique increase in response to DA at a time when hypothalamic LRF secretion is assumed to be elevated suggests that DA may exert its effect by inhibiting LRF release. The inhibition of PRL release by DA is correlated with endogenous E2 levels (r equal 0.685) as well as basal PRL levels (r = 0.878). Rebound release of PRL occurs in all three groups of women on termination of the DA infusion, but the magnitude was greatest in Day 14 subjects with the highest endogenous E2 levels. These data suggest that while E2 seems to augment the sensitivity of PRL inhibition by DA, its does not seem to directly influence gonadotropin sensitivity to DA inhibition. The selective hypersensitivity of both LH and FSH to DA observed on the day before midcycle LH peak is consistent with a reduction in LRF neuronal inhibition by tuberoinfundibular DA neurons at this time.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 122409     DOI: 10.1210/jcem-47-3-494

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Heterogeneity of serum prolactin in patients with menstrual disorder in conjunction with hyperthyroxinemia.

Authors:  H Tamai; O Mizuno; A Takaki; K Kiyohara; G Komaki; S Matsubayashi; K Kuma; L F Kumagai; S Nagataki
Journal:  J Endocrinol Invest       Date:  1991-09       Impact factor: 4.256

2.  Similarity between the effects of suprachiasmatic nuclei lesions and of pinealectomy on gonadotropin release in ovariectomized, sulpiride-treated and melatonin-replaced rats.

Authors:  D Acuña-Castroviejo; B Fernández; J L Castillo; C M del Aguila
Journal:  Experientia       Date:  1993-09-15

3.  Influence of dopaminergic mechanisms on 24-hour secretory patterns of prolactin, luteinizing hormone and testosterone in recumbent men.

Authors:  J R Sowers; S P Viosca; C Windsor; S G Korenman
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

4.  Catecholaminergic interactions in the regulation of thyrotropin (TSH) secretion in man.

Authors:  M F Scanlon; M D Rodriguez-Arnao; M Pourmand; D J Shale; D R Weightman; M Lewis; R Hall
Journal:  J Endocrinol Invest       Date:  1980 Apr-Jun       Impact factor: 4.256

5.  Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.

Authors:  G M Prelević; M I Würzburger; L A Perić
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

6.  Dopamine decreases release of luteinizing hormone releasing hormone from superfused rat mediobasal hypothalamus.

Authors:  K Tasaka; A Miyake; T Sakumoto; T Aono
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

Review 7.  New concepts in the regulation of hypothalamic gonadotropin releasing hormone (GnRH) secretion.

Authors:  D D Rasmussen
Journal:  J Endocrinol Invest       Date:  1986-10       Impact factor: 4.256

8.  Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.

Authors:  G M Prelević; M I Würzburger; L A Perić
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

9.  Effects of increased central dopaminergic tonus on gonadotropin secretion.

Authors:  P Travaglini; C Montanari; M Ballabio; R Elli; R C Scaperrotta; G Faglia
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

10.  Effect of human prolactin administration on gonadotropin and thyrotropin secretion in normal men.

Authors:  M E Molitch; R W Rebar; C P Barsano
Journal:  J Endocrinol Invest       Date:  1993-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.